Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma

International Journal of Oncology
Kazuki IwamotoHiroyuki Hamakawa

Abstract

In our previous study, ribonucleotide reductase M2 (RRM2) was identified as a cancer-related gene commonly overexpressed in human oral squamous cell carcinoma (OSCC) cell lines. Herein, we attempted to determine whether targeting RRM2 may be a plausible therapeutic approach for the treatment of patients with OSCC. First, we examined the expression levels of RRM2 in human OSCC cell lines and tissues. Overexpression of RRM2 in OSCC was confirmed by western blot analysis. Subsequently, we investigated the effects of a synthetic small interfering RNA specific for RRM2 and gemcitabine (GEM), an inhibitor of RRM2 enzymatic activity, on the growth of human OSCC cell lines and primary cultured cells. Targeting RRM2 by RNA interference almost completely suppressed the expression of RRM2 and markedly suppressed the growth of both types of cells by >54.8%. GEM also reduced the growth rate of these cells by >83.0%. Finally, we evaluated the antitumor effects of GEM, cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (DOC) against OSCC cells using the collagen gel droplet embedded culture drug sensitivity test. OSCC cells were more sensitive to GEM and DOC than to CDDP and 5-FU, regardless of the expression level of RRM2 mRNA. These res...Continue Reading

References

Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·H FanJ A Wright
Jun 13, 1998·Journal of the National Cancer Institute·J Rubin GrandisD J Tweardy
Jul 6, 2002·Science·I Bernard Weinstein
Feb 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Aguilar-PonceJ De la Garza
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott WadlerMario Sznol
Apr 13, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A A DesaiM J Ratain
Feb 10, 2006·The New England Journal of Medicine·James A BonnerK Kian Ang
Aug 22, 2006·Current Cancer Drug Targets·J ShaoY Yen
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Sep 30, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C M L van HerpenJ B Vermorken
Jul 2, 2009·International Journal of Cancer. Journal International Du Cancer·Shlok GuptaWilliam J Mackillop
Aug 8, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Masahiko HigashiyamaHisayuki Kobayashi
Aug 17, 2010·International Journal of Oral and Maxillofacial Surgery·S ShintaniY Kurokawa
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Jul 28, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sahar A SaddoughiBesim Ogretmen
Feb 22, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Mohammad Aminur RahmanDong M Shin
May 31, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mohammad Aminur RahmanDong M Shin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.